Ohar J, Polatty C, Robichaud A, Fowler A, Vetrovec G, Glauser F
Chest. 1985 Oct;88(4 Suppl):263S-265S.
The use of systemic vasodilator drugs in reducing pulmonary artery pressures in patients with pulmonary hypertension is controversial. The effect of hydralazine in four patients with pulmonary hypertension resulting from interstitial lung disease (group 1) and nifedipine in four patients with pulmonary hypertension secondary to progressive systemic sclerosis (group 2) was investigated. Hydralazine blunted exercise induced elevations in pulmonary arterial pressures in individual group 1 patients; nifedipine failed to effect significant salutory hemodynamic changes in any group 2 patients.
全身性血管扩张药物用于降低肺动脉高压患者的肺动脉压力存在争议。研究了肼苯哒嗪对4例间质性肺疾病所致肺动脉高压患者（第1组）的作用以及硝苯地平对4例进行性系统性硬化症继发肺动脉高压患者（第2组）的作用。肼苯哒嗪可抑制第1组个别患者运动诱发的肺动脉压力升高；硝苯地平未能使第2组任何患者出现显著有益的血流动力学变化。
